ALGORAE PHARMACEUTICALS LIMITED — Director's Dealing 2019

Dec 5, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Living Cell Technologies Limited
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ken Taylor
Date of last notice	13 December 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct	or	indirect	Direct	Direct
interest
Nature	of	indirect	n/a
interest
(including registered
holder)
Note: Provide details of the
circumstances giving rise to the
relevant interest.
Date of	change		4 May		2019 – 1 July 2019
No. of securities held				Unlisted options		Exercise Price	Expiry Date
prior to	change				250,000	$0.100	01-Jul-20
					250,000	$0.100	01-Jul-21
					100,000	$0.140	01-Jul-20
					100,000	$0.190	01-Jul-21
					400,000	$0.075	04-May-19
					400,000	$0.100	04-May-19
					600,000	$0.113	01-Jul-19
					250,000	$0.0487	13-Dec-21
					Total
					2,350,000
Class			Unlisted Options

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired		nil	nil
Number disposed		1,400,000 unlisted options
Value/ConsiderationNote: If consideration is non-cash,providedetailsandestimated valuation		n/a
No. of securities heldafter change				Expiry Date01-Jul-2001-Jul-2101-Jul-2001-Jul-2113-Dec-21
		Unlisted options	Exercise Price	Expiry Date
		250,000	$0.100	01-Jul-20
		250,000	$0.100	01-Jul-21
		100,000	$0.140	01-Jul-20
		100,000	$0.190	01-Jul-21
		250,000	$0.0487	13-Dec-21
		Total 950,000
Nature of changeExample: on-market trade, off-markettrade,exerciseofoptions, issue of securitiesunder dividend reinvestmentplan, participation in buy-back		Lapse of unlisted options as detailed above.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3